• IN8bio’s third-quarter 2026 net loss widened 19% year over year to $4.59 million.
• R&D expenses rose 24% year over year to $2.6 million, primarily due to preclinical costs for its T cell engager platform.
• Cash fell 48% to $13.97 million at September 30, 2026, from December 31, 2025.
• Initial animal data for INB-619 remain on track for release by year-end 2026, with preclinical development targeting cancer and autoimmune diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611051601PRIMZONEFULLFEED9871631) on November 05, 2026, and is solely responsible for the information contained therein.